December 28, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a Korea-based biotech company, announced the launch of a pilot study to evaluate a new method for early detection of cancer in women who have completed treatment for triple-negative breast cancer (TNBC) and show no radiographic signs of metastases.
December 2, 2015 – Cynvenio announces that it has entered into a strategic collaboration with the Institute of Regional Health Research for the Region of Southern Denmark at the University of Southern Denmark to conduct a wide array of clinical cancer trials using Cynvenio’s Triple Play LiquidBiopsy® platform.
October 1, 2015 – Cynvenio Biosystems, Inc. announces that it has developed, validated, and fully implemented a PD-L1 (Programmed Death-Ligand 1) assay for circulating tumor cells (CTCs) obtained via its LiquidBiopsy® technology for several tumor subtypes.
September 29, 2015 – Cynvenio Biosystems, Inc. and ATGen Global, a private biotech company in Korea that manufactures and supplies a wide array of recombinant proteins and antibodies worldwide, announces the companies a collaborative partnership to bring ATGen’s NK Vue™ test to the US market.
September 8, 2015 – Cynvenio Biosystems, Inc. announces that the Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to its laboratory. Cynvenio has been certified by CLIA, the U.S. Clinical Laboratory Improvement Amendments, since 2013.
September 3, 2015 – Cynvenio Biosystems, Inc. today announced it has hired Paul Y. Song, M.D as Chief Medical Officer to oversee translational and clinical research programs at Cynvenio.
June 18, 2015 – Cynvenio Biosystems, Inc. announces a partnership with newly launched Cure Forward, a patient activation company based in Cambridge, Massachusetts.
June 15, 2015 – Cynvenio Biosystems, Inc. announces the completion a $25.5 million Series B equity financing. Proceeds from the investment will be used to advance the company’s clinical development and commercialization programs. The Series B round was led by Livzon Pharmaceutical Group, Inc. a diversified drug, diagnostics and healthcare company based in Zhuhai, P.R. China. Other investors included Greenwoods Private Equity Funds (Shanghai) and Syno Capital (New York), among others.
April 13, 2015 – Cynvenio Biosystems, Inc. to present recent findings that establish that both CTC DNA and cfDNA can be used as informative and complementary data types for the analysis of tumor-associated mutations by next generation sequencing (NGS) at next month’s third international Molecular Diagnostics Europe event in Lisbon, Portugal.
March 15, 2015 - GEN Magazine profiles Cynvenio and the LiquidBiopsy platform. The article identifies that LiquidBiopsy is on the path to mainstream usage, buoyed by the efficacy of molecular data in improving outcomes.
Jan. 26, 2015 - With evidence building that monitoring a tumor's mutational landscape can be done by evaluating circulating tumor DNA or circulating tumor cells, companies are increasingly looking to move into the liquid biopsy market. Over the last month, the larger players in cancer genomics have all announced their intentions to get into the market, as well.
January 13, 2015 - Thermo Fisher Scientific announces it has signed an agreement with Cynvenio for rights to distribute its LiquidBiopsy platform. The addition of Cynvenio’s rare cell enrichment technology complements Thermo Fisher’s Ion Torrent Personal Genome Machine (PGM) workflow and positions the company as the only one in the industry to offer a comprehensive sample-to-genomic data solution for research using a single blood draw for analysis of circulating tumor cells (CTC), cell-free DNA (cfDNA) and normal DNA in less than 48 hours.
January 02, 2015 – Cynvenio announces nationwide availability of its LiquidBiopsy® platform, which utilizes a blood sample to perform sequence analysis and genomic reporting. This platform gives doctors and cancer researchers the ability to perform next-generation sequencing (NGS) on rare populations of circulating tumor cells and cell-free DNA from whole blood.